Owning the right high-yield dividend stocks can help investors sleep easier at night amid a volatile market like the one we're in right now. As long as passive income remains steady, investors won't have to sell off their core investment holdings to pay their bills.

Swiss drugmaker Novartis (NYSE: NVS), could be an ideal fit within an income investor's portfolio. Let's take a look at Novartis' fundamentals to better understand why it could be a part of an income investor's portfolio. And let's also check out the valuation to answer whether the stock is currently a buy.

Novartis' products reach almost 800 million people each year around the world. (That includes Sandoz, the company's consumer health division which will be spun off.) With this staggering statistic in mind, it's no wonder Novartis' $197 billion market capitalization positions it as the seventh-largest pharmaceutical company on the planet.

Continue reading

Source Fool.com